Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Neurona Therapeutics Inc.
Headquarters: South San Francisco, CA, United States of America
Website: http://www.neuronatherapeut...
Year Founded: 2008
Status: Private
BioCentury | Apr 4, 2025
Finance
Isomorphic’s $600M funding among four megarounds: Finance Report
Other nine-digit financings go to Airna, Atsena, Neurona
BioCentury | Jun 28, 2024
Management Tracks
Forbion taps Dyne vet Brumm to guide growing U.S. presence
Plus: Edward Dulac to become CFO at Intellia, and updates from Altimmune, Bayer, Compass, Sensorion and Neurona
BioCentury | Jun 12, 2024
Management Tracks
Mills to step down as RegenxBio CEO, becomes chair
Plus: Harald Reinhart retires at Zai Lab and updates from Skyhawk, Crossject, Neurona and Coulter Partners
BioCentury | Feb 9, 2024
Finance
Venture report: Scion’s launch, rounds for Neurona, Attralus and Basking
New firm, affiliated with NYC-based Petrichor, will put $310M fund toward company creation
BioCentury | Jan 26, 2024
Management Tracks
Karuna vet Paul among new Third Rock venture partners
Plus: three new executives at Soleno and updates from Zentalis, Slingshot, Actio, Kronos, Osivax, Cellular Origins and ConcertAI
BioCentury | Jul 26, 2022
Management Tracks
Rakhit to succeed Third Rock’s Celniker at Flare
Plus Generate hires Goldman Sachs veteran Jason Silvers as CFO, and updates from HotSpot, Berkeley Lights and more
BioCentury | May 27, 2022
Regulation
May 26 Quick Takes: Reata therapy under priority review for Friedreich’s ataxia
Plus FDA approves Servier’s Tibsovo and updates from Avadel, HHS and more
BioCentury | Dec 14, 2021
Management Tracks
CEO Ford elected chairman at Abbott
Plus: Altimmune, Inivata, ObsEva, Stemirna and more
BioCentury | Jun 29, 2021
Deals
June 28 Quick Takes: STARs aligning for BeiGene trifecta; plus venture money for Neurona, Vita, Lyndra, Currus and Eikonoklastes
Monday’s authorization to list on the Shanghai Stock Exchange’s STAR market sets BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) up to add its third listing, pending approval by China Securities
Items per page:
1 - 10 of 16